Date of Presentation
5-4-2023 12:00 AM
College
School of Osteopathic Medicine
Poster Abstract
Tranexamic acid is a synthetic reversible competitive inhibitor that exerts its action on plasminogen, preventing plasmin formation and deterring fibrinolysis.1 Current FDA-approved indications of TXA include heavy menstrual bleeding and short-term blood loss prevention in patients with hemophilia following tooth extraction.1 TXA has more recently been utilized in the management of massive hemorrhagic trauma patients despite this being an off-label use. While TXA has shown promise as a hemostatic agent for this patient population, considerations in the pre-hospital and hospital settings must be examined for its integration into massive hemorrhage protocols.
Keywords
Tranexamic Acid, Hemorrhage, Trauma, Wounds and Injuries, Off-Label Use
Disciplines
Emergency Medicine | Medicine and Health Sciences | Organic Chemicals | Other Analytical, Diagnostic and Therapeutic Techniques and Equipment | Pathological Conditions, Signs and Symptoms | Trauma
Document Type
Poster
Included in
Emergency Medicine Commons, Organic Chemicals Commons, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Pathological Conditions, Signs and Symptoms Commons, Trauma Commons
Management and Considerations in the Usage of TXA in Hemorrhagic Trauma Patients
Tranexamic acid is a synthetic reversible competitive inhibitor that exerts its action on plasminogen, preventing plasmin formation and deterring fibrinolysis.1 Current FDA-approved indications of TXA include heavy menstrual bleeding and short-term blood loss prevention in patients with hemophilia following tooth extraction.1 TXA has more recently been utilized in the management of massive hemorrhagic trauma patients despite this being an off-label use. While TXA has shown promise as a hemostatic agent for this patient population, considerations in the pre-hospital and hospital settings must be examined for its integration into massive hemorrhage protocols.